title: [Clinical analysis of 10 patients with de novo CD5 positive diffuse large B cell lymphoma].
abstract: To explore the clinical characteristics, diagnosis, treatment outcome and prognosis of de novo CD5 positive diffuse large B cell lymphoma (CD5(+)DLBCL), clinical data of 10 patients with pathologically confirmed CD5(+)DLBCL were retrospectively analyzed. The results indicated that 9 out of 10 patients were older than 60 years. All cases were in III/IV stages according to Ann-Arbor Staging System. Bone marrow biopsy with immunohistochemistry showed lymphoma involvement in 5 cases. Nine patients received chemotherapy with anti-CD20 monoclonal antibody (Rituximab) except one. Five cases achieved CR, two cases achieved PR, two cases achieved SD, one case achieved PD. Eight cases died within 2 years because of relapse or disease progression, in which 3 cases developed central nervous system lymphoma. The median survival time was 16 (1-23) months, 2-year survival rate was 20.40%. It is concluded that de novo CD5(+) DLBCL is rare in clinic, but it is a kind of highly aggressive lymphoma with poor prognosis. So, new treatment strategy should be explored.
authors.affiliation: Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, Guangdong Province, China.
authors.forename: Qian
authors.initials: Q
authors.lastname: Zhang
authors.forename: Hong-Yu
authors.initials: HY
authors.lastname: Zhang
authors.forename: Feng-Luan
authors.initials: FL
authors.lastname: Zhong
authors.forename: Wen-Li
authors.initials: WL
authors.lastname: Zhang
authors.forename: Lei
authors.initials: L
authors.lastname: Xu
authors.forename: Jia
authors.initials: J
authors.lastname: Feng
authors.forename: Qing-Xiang
authors.initials: QX
authors.lastname: Meng
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D018956:CD5 Antigens / Q000378:metabolism*; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D000069283:Rituximab; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018956:CD5 Antigens; D000069283:Rituximab